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Background:  Survivin is thought to contribute to stem cell maintenance partly by a hypomethylation mechanism.   
This study attempted to elucidate the signal transduction pathway of adipocyte-derived stem cells (ASCs) by using 
a demethylating agent, 5-aza-2'-deoxycytidine (ADC), to analyze the survivin, MEK/ERK, c-Myc and p53 gene 
expression. 
Methods:  Demethylation in the ASCs was induced by 1 μM ADC treatment. RT-PCR for survivin mRNA was 
preformed, before and 24, 48 and 72 hours (hr) after ADC treatment.  Western blotting analysis was performed for 
p53, survivin, unphosphorylated and phosphorylated (p)-MEK, and p-ERK. Immunohistochemistry for ERK and 
survivin was done to evaluate the localization of the proteins. 
Results:  ADC inhibited the population growth of the ASCs and it increased the number of apoptotic cells 24, 48, and 
72 hr after treatment.  ADC treatment slightly decreased the expression of survivin mRNA after 48 hr and its level was 
restored after 72 hr of treatment.  Otherwise, the level of survivin protein gradually increased up to 48 hr and it was 
decreased at 72 hr.  The levels of p–MEK and p53 were increased time-dependently.  c-Myc and p-ERK were elevated 
after ADC treatment and their highest levels were seen 48 hr after treatment.  The ADC treatment increased the 
nuclear expression of ERK and survivin in the ASCs. 
Conclusions:  The overexpression of p-MEK/ERK, p53, and c-Myc increased the survivin protein expression of the 
demethylated ASCs.  These results suggest that demethylation could alter the expression of survivin, and p53, c-Myc 
and the MAPK (MEK/ERK) pathway might play a role in survivin’s regulation in ASCs.  (Korean J Anesthesiol 2010; 
58: 383-390)
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Introduction
    Survivin is located in chromosome 17q25, and survivin is 
a new member of the inhibitor of apoptosis (IAP) family. It is 
predominantly expressed in fetal tissue, but it is also found 
in many common human cancers [1-4]. Survivin inhibits the 
terminal effectors of apoptosis and it also inhibits the induction 
of apoptosis by Fas, Bax and caspases [1-4]. 
    In addition, survivin has emerged as a unique regulator of cell 
death through its response to growth factors, such as mitogen-
activated protein kinase (MAPK) [1-4]. The transcriptional c-Myc 
is an oncogene that lies downstream of the MAPK pathway, 
suggesting a possible role for transcriptional c-Myc in survivin’s 
regulation [2,5-7]. The MEK/ERK pathway can also modulate 
the activity of many proteins involved in apoptosis such as 
survivin [1-6]. p53 couples apoptosis to mitogenic signals and 
the survivin pathways [3-7]. Survivin contains a canonical CpG 
island that has been described as being epigenetically regulated. 
Recently there was a report showing that demethylation of 
the survivin promoter by decitabine results in p53-dependent 
survivin repression and that p53 binding can be inhibited by 
DNA methylation. De-repression by methylation is a general 
mechanism of p53 regulation. Demethylation induced by 
decitabine is traditionally thought to be active in tumors by 
allowing the re-expression of tumor suppressor genes [8]. Wang 
and Dick suggested that oncogenic mutation and epigenetic 
defects could be inherited from transformed stem cells, giving 
rise to some populations that have been observed in many 
malignant tumors [9]. As it is speculated that stem cells can 
possess neoplastic-like properties and the expressions of the 
survivin-apoptotic pathway may show the same properties 
in stem cells and cancer cells [9-11], this study attempted to 
elucidate the signal transduction pathway of stem cells by a 
demethylating agent, 5-aza-2'-deoxycytidine (ADC), to analyze 
the survivin, MEK/ERK, c-Myc and p53 gene expressions.
Materials and Methods
Chemicals 
    Dulbecco's modified Eagle's medium (DMEM), 0.25% 
trypsin-EDTA solution, sodium bicarbonate solution, bovine 
serum albumin (BSA), 3-[4,5-dimethythiazol-2-yl]2,5-diphenyl 
tetrazolium bromide (MTT), propidium iodide, ethidium 
bromide, acridine orange, rhodamine 123, agarose, β-actin 
antibody and ADC were purchased from Sigma Chemicals Co. 
(St. Louis, MO, USA). Fetal bovine serum (FBS) and antibiotic/
antimycotic solution were purchased from Gibco (Gibco, USA). 
Sodium phosphate (monobasic and dibasic), sodium chloride, 
sodium hydroxide, sodium carbonate, hydrochloric acid and 
methanol were purchased from Sisco Research Laboratories 
(Mumbai, India). The primary antibodies against c-Myc, 
p53 and survivin were purchased from Dako (Amsterdam, 
Netherlands), ERK and MEK were purchased from Genzyme 
(San Francisco, CA, USA).
Human adipose-derived mesenchymal stem cells 
    Adipose-derived mesenchymal stem cells (ASCs) (from Dr. 
Young-il Yang) were isolated from the lipoaspirates of patients 
undergoing cosmetic liposuction, as described by Zuk et al. [12]. 
In accordance with a consensus reached by the investigators, 
the author referred to this adherent cell population as ASCs. 
Briefly, the tissue was digested for 45 min with 0.075% 
collagenase I (Gibco, USA). The stromal-vascular fraction was 
separated from the remaining fibrous material and the floating 
adipocytes by centrifugation at 300 g. The sedimented cells were 
filtered through a 100 µm pore filter. Erythrocyte contamination 
was reduced by performing density gradient centrifugation with 
Bicoll (Biochrom). High contamination with erythrocytes was 
found to markedly decrease cell adherence and proliferation. 
A preceding density gradient separation procedure provided 
a better yield of adherent cells than did treatment with an 
erythrocyte lysing buffer. For initial cell culture and expansion 
of the cells, DMEM with a physiologic glucose concentration 
(100 mg/dl) supplemented with 10% fetal calf serum (FCS; 
PAA) was used. The primary cell isolates and cultured cells were 
characterized as described by Brzoska et al. [13]. The cultured 
ASCs were CD29+, CD44+, CD49a+, CD73+, CD90+, 
CD105+, CD166+, and CD14-, CD31-, CD45-. The in vitro 
differentiation potential of the ASCs was proven by using 
specific media. For these experiments, the 2nd–5th passage of 
the ASCs was used. 
Cell culture 
    The ASC line was from Dr. Young-il Yang. The cells were grown 
in T75 culture flasks containing DMEM supplemented with 
10% FBS, 100 units/ml penicillin and 100 units/ml streptomycin 
in a humidified 5% CO2 atmosphere at 37
oC. Upon reaching 
confluence, the cells were detached using Trypsin-EDTA 
solution. 
Cell proliferation assay 
    Proliferation of the ASCs was assessed by MTT assay. The 
cells were plated in 24-well plates at a concentration of 5 × 
10
4 cells/well. Twenty-four hr after plating, they were washed 
twice with 500 µl of serum-free medium and then they were 
starved by incubation in serum-free medium for an hour at 385 www.ekja.org
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37
oC. After starvation, the cells were treated with ADC at 0.5, 1, 
2, and 2.5 um concentrations for 24, 48, and 72 hr. At the end of 
treatment, the media from the control and ADC-treated cells 
were discarded and 500 µl of MTT containing DMEM (0.5 mg/
ml) was added to each well. The cells were then incubated for 4 
hr at 37
oC in a CO2 incubator. The MTT-containing medium was 
then discarded and the cells were washed with 1× phosphate-
buffered saline (PBS; 1 ml). The crystals were then dissolved by 
adding 500 µl of solubilization solution and this was effectively 
mixed by pipetting up and down. The spectrophotometrical 
absorbance of the purple blue formazan dye was measured 
using a microplate reader at 620 nm. The optical density of each 
sample was then compared with the control optical density and 
the graphs were plotted. Based on MTT assay, the dose of 1 um 
ADC treatment was selected for further studies because this 
dose was below the IC50 (50% inhibitory concentration) value 
of ADC for the ASCs. 
ADC treatment 
    The cells were subjected to cell cytotoxic assay against ADC 
with various dosages of ADC. A 1 uM dosage was found to be 
most appropriate dosage for this study with using ASC.  The 
appropriate number of the cells (1 × 10
4) was seeded onto 96-
well plates and the cells were treated with 1 uM dose of ADC 
for 24, 48 and 72 hr. Afterwards the cells were detached with 
trypsin-EDTA and the plates were rinsed and the cells were 
collected. The cells were stained with 0.4% trypan blue. The 
viable cells were calculated under the hemocytometer. 
RNA isolation 
    The ASC cells from the same isolation and in the same passage 
were identically treated. The cells were grown to subconfluence 
(70%), washed and kept in serum-starved for 2 hr. In brief, the 
cells were lysed using 10 mM Tris pH 7.4, 0.1% SDS, 0.1% Tween 
20, 0.5% TritonX100, 150 mM NaCl, 10 mM EDTA, 1 M urea, 10 
mM NEM, 4 mM benzamidine, and 1 mM PMSF and then they 
were collected by scraping. 
    The total RNA was isolated from each of the samples after lysis 
in quanidinium isothiocyanate and phenol extraction using 
the commercial kit (Trizol, Invitrogen Laboratories, SanDiego, 
USA). 
Reverse-transcription polymerase chain reaction (RT-
PCR) for detection of survivin mRNA
    The cDNA was synthesized from 4 µg of total RNA in a 25 µl 
reaction mixture containing 6 µl of 5X reverse transcriptase 
reaction buffer, oligo (dT) (100 pmol/ul) 1µl, 10 mM dNTP 4 
µl, 40 unit/µl of RNAsin and 0.5 µl (200 units/L) of Moloney 
leukemia virus reverse transcriptase (MMLV RTase). The 
mixture was incubated at 4
oC for 60 min heated to 94
oC for 3 
min and then chilled on ice. To test the cDNA integrity, GADPH 
was amplified in each of the samples. All the oligonucleotide 
primers were synthesized by and purchased from the Bioneer 
Co (Taejun, Korea). The oligonucleotide primers were solu-
bilized in TE buffer to the concentration of 100 pmol/µl. The 
aliquots were diluted to 10 pmol/µl before use.  To ensure that 
the RNA was not degraded, a PCR assay with primers specific 
for beta-actin cDNA was carried out for each of the cases under 
the following cycling conditions: 25 cycles of 30 sec at 94
oC, 
30 sec at 60
oC and 30 sec at 72
oC with pre-denaturation for 2 
min at 94
oC and post-extension at 72
oC. A 10 µl, aliquot of each 
reaction mixture was fractionated on 1% agarose gel and the 
results were visualized with ethiumbromide staining. cDNA 
was synthesized by random priming using less than 1 µg of 
total RNA as a template. As an internal standard, a fragment 
of human G3PDH was amplified by PCR using the forward 
primer 5'-ACC ACA GTC CAT GCC ATC AC-3' and the reverse 
primer 5'-TCC ACC ACC CTG TTG CTG TA-3' which gave a 
PCR product of 450 bp. The PCR amplification was performed 
in a final volume of 20 µl which was comprised of 1 µl of the 
reverse transcriptase reaction mix, 3 pmol each of the 5' and 3' 
primers for the survivin or the G3PDH genes, 160 µM of deoxy 
nucleotide triphosphate, 1 mM MgSO4 and 0.3 units of Taq DNA 
polymerase in reaction buffer. The PCR was performed with an 
initial denaturation step at 94
oC for 2 min followed by 30 cycles 
of 20 sec at 94
oC for denaturation, 30 sec at 68
oC for annealing 
and 45 sec at 72
oC for extension. The final extension step was 
prolonged to 5 min at 72
oC. The PCR products were separated 
on 2% agarose gels by electrophoresis. 
Direct DNA Sequencing of the PCR products 
    The wizard plus SV miniprep kit (Quazen, Munik, Germany) 
was used for the template DNA preparation for sequencing after 
subcloning the RT-PCR products. An automatic DNA sequencer 
(ABI sequencer 3700, Macrozen, Seoul, Korea) was used for 
sequencing. The sequence data were analyzed by the NCBI 
(NIH, USA) Blast search program. 
Western blot analysis 
    The western blot analysis for the protein expression in the ASC 
cells was assessed using the following method. Approximately 
50 µg of protein was mixed with an equal volume of 2× sample 
buffer, this was boiled for 5 min at 95
oC, cooled, loaded on 
each lane of an 8-15% polyacrylamide gel, and separated by 
sodium dodecyl sulphate–polyacrylamide gel electrophoresis 386 www.ekja.org
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(SDS-PAGE) at room temperature. The resolved proteins were 
electrophoretically transferred to nitrocellulose membranes 
which were then blocked in 5% nonfat milk in Tris-buffered 
saline with 0.1% Tween 20 (TBS-T) for 1 hr at room temperature, 
and then the proteins were probed with the following primary 
antibodies c-Myc (dilution 1 : 500), p53 (rabbit polyclonal 
antibody at a dilution of 1 : 1,000), ERK (rabbit polyclonal 
antibody at a dilution of 1 : 500), p53 (rabbit polyclonal antibody 
at a dilution of 1 : 1,000), MEK (mouse monoclonal antibody 
at a dilution of 1 : 500), survivin (mouse monoclonal antibody 
at a dilution of 1 : 500), and β-actin (mouse monoclonal 
antibody at a dilution of 1 : 2,000), this was performed overnight 
at 4
oC. Blots were then extensively washed with TBS-T and 
they were incubated with the respective (anti-goat, anti-rabbit 
and anti-mouse) horseradish peroxidase-labeled secondary 
antibodies (Genei, Bangalore, India) at dilution of 1 : 2,000 for 
1 hr at room temperature. After thorough washes in TBS-T, 
the bands were visualized by treating the membranes with 
3,3'-diaminobenzidine tetrahydrochloride (Sisco Research 
Laboratories). The membranes were photographed and next 
quantified using image analysis software (NIH, Bethesda, MD, 
USA). The densitometry data presented in the bar graphs are 
the 'fold change' as compared with that of the control in each 
case. 
Statistical analysis
    The results were analyzed using SPSS software (version 17, 
Stanford, SC, USA) and the difference between the protein 
levels of the treated and untreated groups was evaluated using 
Student’s t-test. Multiple groups were compared using the one-
way analysis of variance (ANOVA) test. P values < 0.05 were 
deemed statistically significant.
Results
Survivin mRNA
    The ASCs expressed survivin mRNA before ADC treatment 
and they still expressed survivin mRNA after treatment, and the 
level was decreased slightly after 48 hr and it was restored after 
72 hr (Fig. 1). 
The protein expression of the genes
    The immunoblotting showed increased levels of the protein 
expression of survivin up to 48 hr after treatment. However, 
its level after 72 hr was decreased to lower than that before 
treatment. The levels of p–MEK and p-ERK were increased 
time-dependently, however these levels at 72 hr were decreased 
to lower than that of before treatment. The expression of 
unphosphorylated ERK was not changed. The expression of 
c-Myc was elevated after ADC treatment and it was highest 
at 48 hr after treatment. The expression c-Myc at 72 hr was 
higher than that before treatment (Fig. 2). The p53 expression 
Fig. 1. The mRNA expression of survivin on ASC with ADC treatment 
by RT-PCR. Survivin mRNA (345 bp) expressed before ADC treat-
ment and still expressed survivin mRNA after treatment, which level 
decreases slightly after 48 hr and restores after 72 hr. -: no treatment 
of ADC.
Fig. 3. Protein expression analysis of p-MEK, p-ERK, c-Myc, p53, 
and survivin in control and ADC-treated ASC as assess by immuno-
blotting and by their respective densitometry data. The comparison 
of each protein level at 24, 48, 72 hr after and before ADC treat  ment 
is as follows: P-p-MEK = 0.08, P-p-ERK = 0.001, P-c-Myc = 0.003, 
P-p53 = 0.004, P-survivin = 0.031, P-p-MEK-survivin = 0.075, P-p-ERK-
survivin = 0.010, P-c-Myc-survivin = 0.003, P-p53-survivin = 0.117.
Fig. 2. The expression of proteins on ASC with ADC treatment by 
Western blotting. All proteins are expressed before treatment, and 
show various change of their expressions after treatment.387 www.ekja.org
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was elevated time-dependently up to 72 hr. ADC treatment 
significantly increased the expression of MEK, ERK, c-Myc, 
p53 and survivin time-dependently as was evident from the 
immunoblotting and the corresponding densitometry data (P < 
0.05). The survivin expression was significantly correlated with 
those of c-Myc (P = 0.003) and p-ERK (P = 0.001) (Fig. 3).
Cell morphology
    ADC inhibited the population growth of the ASCs and the 
percentage of apoptotic cells was increased at 24, 48, and 72 hr 
after treatment (Fig. 4). The immunohistochemistry showed 
that the nuclear expressions of ERK and survivin were increased 
after ADC treatment (Fig. 5, 6).
Discussion
    The role of survivin associated with the MAPK pathway, c-Myc, 
and p53 has been reported for malignant tumor, but it still is not 
fully understood [1-6]. Recently, the concept of “cancer stem 
cell” has emerged on the basis that some populations of cancer 
cells have stem cell-like properties [14-17]. The aim of this 
study was to investigate the effect of the demethylating agent 
ADC on survivin and its related proteins in a stem cell pathway 
using ASCs. In the current study, the ASCs had expressed 
survivin mRNA before ADC treatment and they still expressed 
survivin mRNA after treatment, and the level of survivin mRNA 
was decreased slightly after 48 hr and it was restored after 72 
hr. This finding is consistent with Fukuda and Pelus’ report 
[18]. They reported that survivin is highly expressed during 
embryonic development, but it is negligibly expressed in most 
adult tissues. The idea Fukuda has put forth is that survivin may 
contribute to stem cell homeostasis. Accordingly, earlier studies 
suggested that survivin was required to preserve the viability of 
hematopoietic progenitor cells [19].
    DNA methylation is a reversible process in which genes can 
Fig. 4. The morphology of ASC. Before ADC treatment (A), 24 hr after ADC treatment (B), 48 hr after ADC treatment (C), 72 hr after ADC 
treatment (D): ADC inhibits population growth of the ASC and the percentage of apoptotic cells increases 24, 48, and 72 hr after treatment.
D C
B A388 www.ekja.org
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Fig. 5. The immunohistochemistry of ERK. Before ADC treatment (A), 24 hr after ADC (B), 48 hr after ADC (C), 72 hr after ADC treatment (D). 
The percentage of apoptotic cells increases 24, 48, and 72 hr after treatment. The number of nuclear translocation of ERK increases.
D C
B A
Fig. 6. The expression of survivin by immunohistochemistry. 48 hr after ADC treatment (A), 72 hr after ADC treatment (B). The maximum level 
of survivin-expressing cells was at 48 hr after treatment, but the nuclear expression increases at 72 hr.
B A389 www.ekja.org
Korean J Anesthesiol Yoon, et al.
be demethylated and restored to their original expression 
and function [20-22]. The DNA methylating agent, ADC is 
thought to inhibit the enzymes that methylate the cytidine 
residues in DNA and demethylate the methylated DNA [21,22]. 
This study showed a gradually increased level of the protein 
expression of survivin up to 48 hr after treatment. However, 
its level at 72 hr was lower than that before treatment. This 
study disclosed the apoptosis was increased maximally at 72 hr 
after ADC treatment, while the nuclear expression of survivin 
was increased. This result can explain the translocation and 
subcellular localization of survivin, that is, when survivin is in 
the cytoplasm it acts to suppress apoptosis, but when survivin is 
in the nucleus it acts as a chromosomal passenger protein at the 
G2/M checkpoint [1-4,11,15] 
    In this study, the p53 expression was elevated time-depen-
dently up to 72 hr after treatment. This finding is consistent with 
the morphological change of increasing apoptosis. p53 protein 
inhibits the growth of tumors by arresting cell proliferation 
and inducing apoptosis [14,15]. The current study showed the 
survivin expression was increased up to 48 hr after treatment 
together with a gradual increase of p53. However, Nabilsi et 
al. reported that demethylation of the survivin promoter by 
decitabine resulted in p53-dependent survivin repression and 
that p53 binding can be inhibited by DNA methylation in the 
endometrial cancer cell line [8]. This opposite result might 
suggest that the expression of survivin in ASCs was regulated via 
a different signal pathway from that of the endometrial cancer 
cell line. There was a report that most methylated ovarian 
cancer is survivin-negative, which means demethylation can 
make some cancers express survivin [23].
    The levels of phosphorylated–MEK and -ERK were increased 
time-dependently, however the levels 72 hr after ADC treat  ment 
were decreased to lower than that before treatment. c-Myc was 
elevated after ADC treatment and its highest level was noted 48 
hr after ADC treatment. The expressed c-Myc level at 72 hr was 
higher than that before treatment.
    In this study, ADC treatment significantly increased (P < 
0.05) the expressions of MEK, ERK, c-Myc, p53 and survivin, 
as is evident from the immunoblotting and the corresponding 
densitometry data. Especially the expression of survivin was 
significantly correlated with those of c-Myc (P = 0.028) and 
ERK (P = 0.010). There are a few previous reports that support 
the results of this current study, although most of the previous 
reports were studied cancer. Carter et al. [24] reported that the 
survivin expression in leukemic cells is regulated by cytokines 
and differentiation-inducing agents and that the modulation 
of major signal transduction pathways, such as the MEK/ERK 
at the mRNA and protein levels. Arango et al. [7] described 
that the c-Myc expression increases the cellular sensitivity to 
DNA damage-induced apoptosis. Seoane et al. [10] presented 
that the c-Myc expression is also important in determining 
the action of p53 in response to DNA damage. A high level of 
c-Myc can favor the apoptosis response to p53 [9]. Accordingly, 
this study showed the p53, and c-Myc related apoptosis in 
ASCs that were damaged by ADC treatment, yet there was 
the concomitantly upregulation of the anti-apoptotic protein, 
survivin. This controversy can be explained by the reports of 
Yuan and Filion that the upregulation of survivin occurred 
during the immotalization of human adult cells [25,26]. The 
ASCs utilized in this study might have immortalized properties, 
although precise further evaluation will be needed to verify 
the current results. Besides, it should be considered that the 
survivin-pathway might be not universal but rather, it is cell or 
tissue-specific and demethylation is also a mechanism affected 
by time and the internal or external environments.
    In conclusion, the overexpression of p-MEK and ERK, p53, 
and c-Myc increased the survivin protein expression of the 
demethylated ASCs. These results suggest that demethylation 
could alter the survivin expression and p53, c-Myc and the 
MAPK pathway might play a role in survivin’s regulation in adult 
mesenchymal stem cells. Therefore, survivin helps maintain the 
homeostasis of adipocyte-derived stem cell. This study presents 
evidence that the expression of multiple gene pathways controls 
this response, including the MEK, ERK, c-Myc and p53 genes. 
Further study with stem cells will be needed to verify these 
results.
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